左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床观察

目的 观察左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床疗效。方法 回顾分析2018年1月~2019年1月在我院诊治的90例子宫腺肌病患者临床资料，采用左炔诺孕酮宫内缓释系统治疗，观察治疗后1个月、3个月、6个月痛经评分、月经量、子宫体积、CA125、Hb以及不良反应。结果 治疗后1个月、3个月、6个月痛评分降低、月经量减少、子宫体积缩小，与治疗前比较，差异有统计学意义（P＜0.05）；治疗后1个月、3个月、6个月CA125水平降低，Hb水平升高，与治疗前比较，差异有统计学意义（P＜0.05）；随诊6个月，4例出现阴道不规则出血，2例出现节育器下移，1例乳房胀痛，不良反应发生率为7.78%，临床给予针对性的处理后好转。结论 左炔诺孕酮宫内缓释系统治疗子宫腺肌病疗效确切，不良反应少，是临床治疗子宫腺肌病的有效安全的保守治疗方法。

Clinical Observation of Levonorgestrel Intrauterine Sustained Release Systemin the Treatment of Adenomyosis

Abstract:Objective To observe the clinical efficacy of levonorgestrel intrauterine sustained release system in the treatment of adenomyosis.Methods The clinical data of 90 patients with adenomyosis diagnosed in our hospital from January 2018 to January 2019 were retrospectively analyzed. The levonorgestrel intrauterine sustained-release system was used to treat the patients 1 month,3 months,6 months after treatment,dysmenorrhea score, menstrual flow, uterine volume, CA125, Hb and adverse reactions.Results The pain scores decreased, the menstrual volume decreased, and the uterus volume decreased at 1 month, 3 months, and 6 months after treatment,the difference was statistically significant (P<0.05); At 1 month, 3 months, and 6 months after treatment, the level of CA125 decreased, and the level of Hb increased. Compared with before treatment, the difference was statistically significant (P<0.05). After 6 months of follow-up, 4 cases had vaginal irregularities bleeding, 2 cases of birth control device moved down, 1 case of breast pain, the incidence of adverse reactions was 7.78%, and the clinical treatment was improved after targeted treatment.Conclusion The levonorgestrel intrauterine system is effective and safe in the treatment of adenomyosis. It is an effective and safe treatment for adenomyosis.